Serum Endocan as a Predictive Marker for Decreased Urine Volume in Peritoneal Dialysis Patients

Oka, Satoru; Obata, Yoko; Sato, Shuntaro; Torigoe, Kenta; Sawa, Miki; Abe, Shinichi; Muta, Kumiko; Ota, Yuki; Kitamura, Mineaki; Kawasaki, Satoko; Hirose, Megumi; Uramatsu, Tadashi; Mukae, Hiroshi; Nishino, Tomoya

doi:10.12659/msm.900693

Cited by 12 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum endocan levels were found higher in CKD patients than healthy subjects and in addition that serum endocan levels were found to be higher in CKD patients with CVD as compared to those without CVD [ 6 ]. In another study, serum endocan levels were observed higher in peritoneal dialysis patients than healthy subjects [ 24 ]. Raptis et al have reported higher serum endocan levels in ADPKD patients with eGFR 45-70 mL/min/1.73 m 2 than ADPKD patients with eGFR >70 mL/min/1.73 m 2 and higher serum endocan levels in ADPKD patients than controls [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease

Ekinci

Büyükkaba

Çınar

et al. 2021

Cureus

View full text Add to dashboard Cite

In this study, we aimed to determine the endothelial dysfunction (ED) and atherosclerosis in patients with autosomal dominant polycystic kidney disease (ADPKD). Materials and methods This study was conducted with 83 subjects (26 male, mean age: 46±11 years) consisted of three groups including ADPKD, hypertension (HT) and healthy control groups. The groups were evaluated in terms of serum endocan and asymmetric dimethylarginine (ADMA) levels, flow-mediated dilatation (FMD), nitroglycerin-mediated dilation (NMD) and carotid intima-media thickness (CIMT). Results Serum endocan and ADMA levels and CIMT were significantly higher while NMD was significantly lower in ADPKD group than control group. FMD and NMD were lower but serum ADMA level was higher in the ADPKD group than HT group; while serum endocan level and CIMT were not significantly different in ADPKD and HT groups. In ADPKD patients, CIMT value and serum endocan and ADMA levels were higher while NMD was lower in patients with eGFR≤60 mL/min/1.73 m 2 than patients with eGFR>60 mL/min/1.73 m 2. Serum ADMA level was higher and NMD was lower in hypertensive ADPKD patients than nonhypertensive ones. Serum endocan level was higher in ADPKD patients with nephrolithiasis and a negative correlation was detected between serum endocan level and 24-hour urine volume. Conclusions Endothelial dysfunction and atherosclerosis are common conditions in ADPKD patients and it was further reinforced in our study. In order to clarify the relationship between serum endocan level and 24-hour urine volume, which is a remarkable finding in our study, larger studies that including the measurement of urine endocan may be useful.

show abstract

Section: Discussionmentioning

confidence: 99%

Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease

Ekinci

Büyükkaba

Çınar

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…In our previous study, plasma and urinary endocan levels were significantly increased in kidney transplant patients with acute antibody-mediated rejection, and patients with high endocan levels showed worse renal survival [ 10 ]. In ESRD patients undergoing peritoneal dialysis, serum endocan levels have a predictive value for decreasing urine volume and showed a significant correlation with clinical characteristics and cardiovascular events [ 24 , 25 ]. However, only a few studies have evaluated endocan in hemodialysis patients [ 26 , 27 ], and the studies were conducted with a relatively small sample size, and did not analyze the association between clinical outcomes and endocan levels.…”

Section: Discussionmentioning

confidence: 99%

“…Although no further analysis was conducted on this result, the following supposition can be made: given that patients in the lower endocan group have shorter hemodialysis (HD) duration than those in the higher endocan group, it is assumed that patients in the lower endocan group have a higher residual renal function. Previous studies reported that endocan levels showed a negative association with residual renal function [ 24 , 25 ]. The result of adding residual renal function to assess dialysis adequacy may differ from our prior result.…”

Section: Discussionmentioning

confidence: 99%

Plasma Endocan as a Predictor of Cardiovascular Event in Patients with End-Stage Renal Disease on Hemodialysis

Kim

et al. 2020

JCM

View full text Add to dashboard Cite

Endocan, a potential biomarker of endothelial dysfunction, is associated with increased cardiovascular risk. We investigated the utility of plasma endocan for predicting cardiovascular risk in end-stage renal disease (ESRD) patients undergoing hemodialysis. Of the 452 patients in the K-cohort, 354 with available plasma endocan levels were enrolled. The correlation between plasma endocan levels and the clinical characteristics of a study population were analyzed. We divided patients into two groups, according to plasma endocan levels, and investigated the predictive value of endocan for the occurrence of cardiovascular events. In a multiple linear regression analysis, plasma endocan levels were positively correlated with previous cardiovascular events and negatively correlated with body mass index, albumin, and triglyceride. Patients with higher plasma endocan levels experienced more frequent cardiovascular events than those with lower plasma endocan levels (12.9% in the lower group vs. 22.7% in the higher group, p = 0.016). Cox proportional hazard models showed that higher plasma endocan levels were an independent predictor of cardiovascular events in ESRD patients on hemodialysis ((hazard ration) HR 1.949, 95% (confidence interval) CI 1.144–3.319, p = 0.014). Our results suggest that plasma endocan level might be a useful biomarker for predicting cardiovascular events in ESRD patients on hemodialysis.

show abstract

“…Whether endocan exerts pro-inflammatory or anti-inflammatory effects on the vascular endothelium remains to be determined. Regardless of its biological functions, plasma endocan has been shown to be correlated with inflammation severity and poor survival in various diseases, such as coronary artery disease, malignancy, chronic kidney disease, IgA nephropathy and sepsis 37–45 .…”

Section: Discussionmentioning

confidence: 99%

Endocan as a marker of microvascular inflammation in kidney transplant recipients

Lee

Kim

Moon

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Endocan is a water-soluble proteoglycan exclusively secreted by vascular endothelium. Endocan levels may be elevated in kidney transplant recipients experiencing antibody-mediated rejection (ABMR), which is characterized by vascular inflammation in transplanted kidney. We evaluated the clinical relevance of endocan as markers of microvascular inflammation in patients who underwent kidney transplantation. Plasma and urinary endocan levels were measured in 203 kidney transplant recipients and were compared across different etiologies of allograft dysfunction and various pathologic scores. Both plasma and urinary endocan levels were significantly higher in patients with acute ABMR than those in patients with normal pathology, acute tubular necrosis (ATN), acute pyelonephritis, BK virus associated nephropathy (BKVN), and T-cell mediated rejection (TCMR). Patients with chronic active ABMR also exhibited significantly higher plasma and urinary endocan levels than patients with long-term graft survival. Scores of glomerulitis and peritubular capillaritis, which are typical features of microvascular inflammation, were significantly elevated in patients with higher plasma and/or urinary endocan levels. Furthermore, plasma and urinary endocan levels could effectively discriminate ABMR from ATN, BKVN, and TCMR. Finally, patients exhibiting high urinary and plasma endocan levels in acute ABMR group showed significantly worse renal survival. Altogether, plasma and urinary endocan levels may serve as potential markers of microvascular inflammation in kidney transplant recipients.

show abstract

Serum Endocan as a Predictive Marker for Decreased Urine Volume in Peritoneal Dialysis Patients

Cited by 12 publications

References 31 publications

Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease

Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease

Plasma Endocan as a Predictor of Cardiovascular Event in Patients with End-Stage Renal Disease on Hemodialysis

Endocan as a marker of microvascular inflammation in kidney transplant recipients

Contact Info

Product

Resources

About